AWM
GALT icon

Avior Wealth Management’s Galectin Therapeutics GALT Stock Holding History

Avior Wealth Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-600
Closed -$774 – 1346
2024
Q4 		$774 Hold
600
– – ﹤0.01% 2227
2024
Q3 		$1.65K Hold
600
– – ﹤0.01% 2005
2024
Q2 		$1.36K Buy
+600
New +$1.82K ﹤0.01% 1996

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Avior Wealth Management's GALT Position: Q1 2025 in Review

Avior Wealth Management sold out of Galectin Therapeutics (GALT) in Q1 2025, closing a stake of 600 shares — an estimated $774 sold.

Avior Wealth Management first reported a position in GALT in Q2 2024 and held it in 3 quarters. The position peaked at $1.65K in Q3 2024. 93 funds tracked by Wall St. Rank hold GALT as of Q1 2025.

  • Avior Wealth Management reported no remaining Galectin Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Avior Wealth Management sold 600 Galectin Therapeutics shares in Q1 2025, an estimated $774.
  • Avior Wealth Management first reported a position in Galectin Therapeutics in Q2 2024 and held it in 3 quarters.
  • Avior Wealth Management's Galectin Therapeutics position peaked at $1.65K in Q3 2024.
  • 93 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2025.

Based on Avior Wealth Management's 13F filing for Q1 2025, filed 21 Apr 2025.